We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pte4.5
Oral Proteolytic Enzymes Research
Too few graded studies
17 peer-reviewed studies
What the evidence says
Too few graded studies
Oral Proteolytic Enzymes doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from medium-quality meta-analyses and randomised trials published 2003–2026 with a typical study size of 138 participants.
Based on 17 studies · 1 meta-analysis · 12 RCTs · 6,438 total participants
Confidence
High confidence
By outcome
Joint pain & arthritisKnee or hip osteoarthritis pain and function: non-inferior to diclofenac in two 6-week trials designed to test that, with fewer side effects. Benefit over placebo rests on one knee trial and one small crossover trial · 3-6 weeks
Too few graded studies7 studies
Injury, surgery & exercise recoveryLess pain after hip replacement and better preserved strength after downhill running in small placebo-controlled trials, but no benefit in a 721-person ankle sprain trial · Days to 1 week
Too few graded studies7 studies
InflammationLower CRP after hip replacement and higher IL-10 in knee osteoarthritis in small trials, with no effect on marathon-induced IL-6, CRP or leukocytes · 1-8 weeks
Too few graded studies6 studies
Safety profile
Too few graded studies5 studies
Pain & analgesia
Too few graded studies4 studies
Oncology & clinical conditions
Too few graded studies3 studies
Urinary tract infection
Too few graded studies1 study
Wound & ulcer healing
Too few graded studies1 study
Heart & blood pressure
Too few graded studies1 study
Active research area
6 studies in the last 5 years · Latest meta-analysis: 2016
200320142026
1RCTCited 20×n=721 · large study2004
In plain English: [The triple combination] was not found to be superior to the three two-drug combinations, the three single substances, or placebo for treatment of patients with acute unilateral sprain of the lateral ankle joint.
Kerkhoffs GM, Struijs PA, de Wit C, Rahlfs VW, Zwipp H, van Dijk CN · Br J Sports Med (2004)
Multicentre, double-blind, randomised factorial trial in 721 people aged 16-53 with acute lateral ankle sprain at 27 European hospitals, comparing rutoside plus bromelain plus trypsin with each two-drug combination, each single substance and placebo
At day 7, median pain fell 60.3% with the triple combination and 73.3% with placebo. Range of motion rose 42.9% with the triple combination and 60% with placebo, and swelling changed -2.30% versus -2.90%
The triple combination was not superior to placebo or to any other arm. Only in a small subgroup treated without an ankle brace was it better than placebo (p = 0.029)
In plain English: Supplementation with rutoside and hydrolytic enzymes before and after a marathon race did not attenuate postrace inflammation or decrease URI incidence in nonelite male marathon runners.
Grabs V, Kersten A, Haller B, Braun S, Nieman DC, Halle M, Scherr J · Med Sci Sports Exerc (2017)
Randomised, double-blind, placebo-controlled trial in 138 healthy male marathon runners: rutoside 600-1200 mg/day, bromelain 540-1080 mg/day and trypsin 288-576 mg/day, or placebo, for 1 week before and 2 weeks after the race
The post-race rise in IL-6 did not differ (median 33.8 versus 35.6 ng/L, p = 0.758), and neither did IL-10, high-sensitivity CRP or leukocytes
Upper respiratory illness in the 2 weeks after the race was no less common (50.0% versus 51.5%, p = 0.859)
In plain English: No treatment effect between the placebo and the HE groups was found either for clinical or MRI parameters.
Baumhackl U, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, Mertin J · Mult Scler (2005)
Randomised, double-blind, placebo-controlled trial in 301 people with relapsing multiple sclerosis, testing oral hydrolytic enzymes such as bromelain, trypsin and rutoside after complete protection in an animal model
No treatment effect was found on clinical or MRI outcomes
The animal-model result did not carry over to people. The abstract does not state the dose or the treatment duration
In plain English: Improvement in pain scores (Lequesne Functional Index) did not differ between subjects treated with [the enzyme combination] or diclofenac, and both treatment groups improved compared to placebo (P < 0.05).
Randomised, double-blind trial in 150 adults with moderate-to-severe knee osteoarthritis: an oral enzyme combination, diclofenac or placebo for 12 weeks
On the primary outcome, the Lequesne index, the enzyme combination and diclofenac did not differ and both improved more than placebo (p < 0.05)
On total WOMAC, a secondary outcome, only diclofenac differed from placebo. The enzyme group used less rescue paracetamol than placebo (p < 0.05)
In plain English: When compared with DIC, OEC showed comparable efficacy and a superior tolerability/safety profile associated with a significantly lower risk of treatment-emergent adverse events, related study discontinuations, and changes in laboratory parameters.
Ueberall MA, Mueller-Schwefe GH, Wigand R, Essner U · J Pain Res (2016)
Individual patient-level pooled reanalysis of six randomised, double-blind trials that enrolled 774 adults with moderate-to-severe knee osteoarthritis, comparing an oral combination of proteolytic enzymes and a bioflavonoid with diclofenac for at least 3 weeks. The six trials include the 103-person knee trial (Akhtar 2004) and the 150-person knee trial (Bolten 2015) cited separately here, so it is not additional to them
The Lequesne index fell from 12.6 to 9.1 with enzymes and from 12.7 to 9.1 with diclofenac. In the full text the difference was 0.31 points (95% CI -0.10 to 0.73) against a 3-point non-inferiority margin, close to the size of the improvement itself. Movement pain fell from 6.4 to 3.8 and from 6.6 to 3.9 on a 0-10 scale
Treatment-emergent adverse events were less frequent with enzymes (14.7% versus 21.1%, p = 0.022), as were discontinuations (5.9% versus 10.2%, p = 0.030), and fewer patients had falls in haemoglobin or rises in liver enzymes
In plain English: Patients administered OEC exhibited significant improvements in KOOS Pain (p=0.0464) and Symptoms (p=0.026) subdomains but not globally.
Henrotin Y, Pap T, Lieten S, Badot V, Dubuc JE, Urbin-Choffray D, von Eynatten M, Johansen OE, Rau S, Brabants K · RMD Open (2025)
Randomised, double-blind, placebo-controlled crossover trial in 45 people with symptomatic knee osteoarthritis: bromelain, trypsin and rutoside, 3 tablets twice a day for 8 weeks, crossing over after a 4-week washout. 43 completed both periods
The combination raised alpha-2-macroglobulin (p = 0.038) and interleukin-10 (p < 0.0001) and lowered urinary CTX-II, a marker of cartilage breakdown (p = 0.038)
KOOS pain (p = 0.0464) and symptoms (p = 0.026) improved, but the overall KOOS score did not. No correction was made for multiple comparisons
In plain English: Non-inferiority of ERC was demonstrated by both primary criteria, LFI (MW = 0.5305; CI-LB = 0.4171) and complaint index (MW = 0.5434; CI-LB = 0.4296).
Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M · Clin Rheumatol (2004)
Randomised, double-blind trial at two centres in 103 people with painful knee osteoarthritis: a combination of bromelain, trypsin and rutoside (n = 52) or diclofenac (n = 51) for 6 weeks
The Lequesne index fell from 13.0 to 9.4 with the enzyme combination and from 12.5 to 9.4 with diclofenac
Non-inferiority to diclofenac was shown on both primary outcomes. That is not superiority, and secondary outcomes showed only a slight tendency in favour of the enzymes
In plain English: However, in this study there was no real difference between PE and DC 100 mg/day, implying an equal benefit-risk relation between the substances.
Klein G, Kullich W, Schnitker J, Schwann H · Clin Exp Rheumatol (2006)
Single-centre, phase III, randomised, double-blind trial in 90 people with painful hip osteoarthritis: an oral enzyme combination (n = 45) or diclofenac 100 mg/day (n = 45) for 6 weeks
WOMAC pain fell 10.3 versus 9.5 points, stiffness 3.9 versus 3.6 and physical function 31.7 versus 29.7 (enzymes versus diclofenac)
Non-inferiority to diclofenac was established on all four primary endpoints. The equivalence tests were not significant, and the authors found no real difference between the treatments
9Systematic ReviewCited 2×2003
In plain English: According to the present state of knowledge, oral proteolytic enzyme treatment does not offer a justified alternative in comparison with NSAID in the anti-inflammatory treatment of rheumatic disease.
Heyll U, Münnich U, Senger V · Med Klin (Munich) (2003)
Systematic review of randomised trials of oral enzyme preparations registered in Germany as anti-inflammatory, compared with NSAIDs in degenerative and inflammatory rheumatic disease
Only three of the eight registered enzyme preparations had been tested in randomised trials, and seven trials were documented well enough to assess
Every trial had severe methodological deficits. Most were run during inpatient rehabilitation alongside extensive other treatment, which does not allow clear conclusions
10Systematic ReviewCited 10×n=3,008 · very large study2021
In plain English: On the basis of existing evidence, there is no clear therapeutic benefit of enzymes neither as supportive therapy nor as part of antineoplastic therapy.
Systematic review of 15 studies with 3,008 cancer patients given proteolytic enzymes such as bromelain, papain and chymotrypsin, mostly by mouth alongside conventional cancer treatment
Outcomes were side effects of cancer treatment, quality of life, anticancer effect and survival
Conflicting results and moderate study quality left the evidence insufficient to show better tolerability of cancer treatment or better treatment efficacy
In plain English: In the [enzyme combination] group, recurrent exacerbation of chronic recurrent uncomplicated cystitis was observed in 12.62% of patients (95% CI: 8.94; 16.29), in the Placebo group - in 24.53% of patients (95% CI: 19.77; 29.28) (p<0.05).
Kupriyanov YuA, Zaitsev AV, Bernikov AN, Khodyreva LA, Pushkar DY · Urologiia (2026)
Double-blind, randomised, placebo-controlled trial at 20 Russian centres in 638 women with an exacerbation of chronic recurrent uncomplicated cystitis. All received a fosfomycin course, plus an oral enzyme combination (n = 320) or placebo (n = 318)
Recurrence occurred in 12.6% on enzymes (95% CI 8.9 to 16.3) and 24.5% on placebo (95% CI 19.8 to 29.3), p < 0.05, and the main symptoms resolved faster
Adverse events were recorded 86 times on enzymes and 105 times on placebo, and laboratory safety values did not differ
12RCTn=118 · medium study2026
In plain English: no differences were observed between groups for any hemostatic marker (all p>0.05)
Schoenfeld J, Grabs V, Nieman DC, Holdenrieder S, Haller B, Halle M, Scherr J · Front Physiol (2026)
Predefined subanalysis of the randomised, double-blind, placebo-controlled marathon trial: rutoside 600-1200 mg/day, bromelain 540-1080 mg/day and trypsin 288-576 mg/day, or placebo, for 1 week before and 2 weeks after the race
In 118 male runners (64 enzymes, 54 placebo) no hemostasis marker differed between groups, including D-dimer, thrombin generation, ADP-induced platelet aggregation and platelet count
Studied in healthy male runners. It does not address people taking anticoagulant or antiplatelet drugs
In plain English: In particular, there was no beneficial effect on radiation-induced early oral mucositis.
Dörr W, Herrmann T · Strahlenther Onkol (2007)
Randomised, placebo-controlled, triple-blind phase III trial at five centres in 69 people having radiotherapy for cancer of the oropharynx or mouth, 61 of whom were analysed. The enzyme product comprised papain 100 mg, trypsin 40 mg and chymotrypsin 40 mg
Maximum mucositis scores did not differ between enzymes and placebo
The average mucositis score over weeks 1-6 favoured placebo, because mucositis started earlier in the enzyme group
In plain English: Pre- and post-operative use of OEC significantly reduced CRP levels and patient self-reported pain.
Vosáhlo J, Salus A, Smolko M, Němcová B, Nordmeyer V, Mikles M, Rau SM, Erik Johansen O · Ther Adv Musculoskelet Dis (2023)
Randomised, double-blind, placebo-controlled exploratory trial in 34 people having elective total hip replacement for osteoarthritis, 33 of whom completed (15 enzymes, 18 placebo). Each tablet held bromelain 90 mg, trypsin 48 mg and rutoside 100 mg, started before surgery and continued to day 42
The CRP area under the curve over days 1-7 was 32% lower with the combination (p = 0.034), with a mean peak of 81.4 versus 106.7 mg/L
Pain at rest over days 1-7 was lower than with placebo (p = 0.005). Analgesic use was lower only numerically
In plain English: Protease supplementation seems to attenuate muscle strength losses after eccentric exercise by regulating leukocyte activity and inflammation.
Randomised, placebo-controlled trial in 29 young adults: 5.83 g a day of a supplement with fungal proteases, bromelain and papain (n = 14) or cellulose placebo (n = 15) for 21 days before a 45-minute downhill run
Knee flexion peak torque was better preserved with the protease supplement at two post-exercise time points (p = 0.033 and p = 0.043)
Serum COX-2, IL-6 and IL-12 were lower in the protease group. The abstract does not report blinding or a muscle soreness outcome
In plain English: A non-significant difference between groups in pain reduction (p = 0.737) and wound healing symptoms (p = 0.554)
Dewan B, Shinde S, Motwani N · Cureus (2025)
Open-label, randomised, multicentre phase IV study in 200 people after clean elective surgery: a tablet of trypsin 48 mg, bromelain 90 mg and rutoside 100 mg, or a trypsin-chymotrypsin tablet, two tablets three times a day for 7 days
Wound signs and pain improved in both groups against baseline (p < 0.001), with pain scores down more than 85% in each
The two combinations did not differ for pain (p = 0.737) or wound healing (p = 0.554). With no placebo group, the improvement cannot be separated from normal post-operative healing
In plain English: Our results indicate that protease supplementation may attenuate muscle soreness after downhill running.
Miller PC, Bailey SP, Barnes ME, Derr SJ, Hall EE · J Sports Sci (2004)
Placebo-controlled trial in 10 matched pairs of men (20 in total) who ran downhill for 30 minutes: two tablets four times a day of a blend containing pancreatic enzymes, trypsin, papain, bromelain and chymotrypsin, or placebo, for 4 days starting the day before
The enzyme group recovered contractile function better and had less delayed-onset muscle soreness than the placebo group
The abstract gives no effect sizes or p-values and does not say whether allocation was randomised